Evidence map›Paper›PMID 41794719›Full record

ArticleJournal of nanobiotechnology2026

Li Sun, Bin Zhu, Ke Zuo, Liyan Bai, Jialiang Lei, Ye Li, Xinyu Liu, Xiaoyu Pan, Juan Li, Aiguo Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Li Sun *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Bin Zhu *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ke ZuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Liyan BaiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jialiang LeiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ye LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xinyu LiuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaoyu PanDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Juan LiNingbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academyof Sciences, Ningbo, 315201, China.
Aiguo WuNingbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academyof Sciences, Ningbo, 315201, China.
Yijun ShenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Yijunshen79@163.com.
Xiaoping XuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xxp0012@ustc.edu.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. shaoli-song@163.com.

Funding

Key Program of National Natural Science Foundation of China U23A20465National Natural Science Foundation of China 12275057National Natural Science Foundation of China 52403213National Natural Science Foundation of China 82272035National Science Foundation for Distinguished Young Scholars of China 32025021Postdoctoral Fellowship Program of CPSF GZC20232791Science and Technology Commission of Shanghai Municipality 23DZ2291400Shanghai Oriental Talents Program Youth Project SSF828085
6 · The paper itself

Abstract

Nectin-4 is markedly overexpressed in urothelial carcinoma (UC) and represents a promising theranostic target for both radiotherapy and positron emission tomography (PET) imaging. The Food and Drug Administration (FDA)-approved Nectin-4-targeted drug, enfortumab vedotin, has demonstrated substantial efficacy in the treatment of UC. Developing a non-invasive quantitative detection technology based on positron emission tomography/computed tomography (PET/CT) imaging is crucial for accurately measuring Nectin-4 expression levels, facilitating precise patient selection, treatment stratification, and efficacy monitoring in UC. In the present study, a series of

Indexed as

Cell Adhesion MoleculesLutetiumNectinsPeptides, CyclicRadioisotopesRadiopharmaceuticalsUrologic NeoplasmsAnimalsCell Line, TumorGallium RadioisotopesHumansMiceMice, Inbred BALB CMice, NudePositron Emission Tomography Computed TomographyTheranostic NanomedicineCell Adhesion MoleculesGallium-68Gallium RadioisotopesLutetiumLutetium-177NECTIN4 protein, humanNectinsPeptides, CyclicRadioisotopesRadiopharmaceuticals68Ga/177Lu-LabeledBicyclic peptideCovalent targeted radioligandsDiagnosis and treatmentNectin-4PET/CTUrothelial carcinoma (UC)

Identifiers

PMID41794719
PMCPMC13081371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.